The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.
Latest Conference Articles
Advertisement
Dr. Diana Do presents data on a novel patient-reported outcome instrument for patients with proliferative diabetic retinopathy with the hope of capturing the burden of the disease and treatment.
The Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Colorado, revealed a variety of advancements in technology, pivotal trials and clinical trial design.
Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.
Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.
Eva Chamorro, PhD, MSc, points out that myopia control spectacle lenses affect the diurnal rhythms in the AL in young adult human and produced a small short-term increase in the AL that varies in intensity and time interval for each of the 3 studied lenses.
THR-687 is currently being evaluated in a phase 2 clinical trial in patients with DME. The first data from the dose-optimization study is expected to be released in the first half of 2022.
Mike Watson, Vice President of OraNet, unpacks some of the most pressing challenges to clinical research in today’s climate.
During a presentation at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Yuichi Hori, MD, PhD, and colleagues found that taping the top border of a surgical mask to a clinicians’ skin reduces the potential for ocular surface damage resulting from expirations of air reaching the ocular surface during the COVID-19 pandemic.
The study found no association between treatment and the risk of chronic kidney disease or end-stage renal disease.
Advertisement
In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting, Osama Ibrahim Hirayama, MD, and colleagues offered results that demonstrating that anisometropia and astigmatic error were greater among the patients with high myopia compared with the other groups. Compared with the subjects with no myopia, those with high myopia reported significantly more dryness, less photophobia, and less pain.
Dr. David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.
The axitinib intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.
Investigators from the New York University Grossman School of Medicine presented data at the ARVO 2022 annual meeting that concluded mapping of the relative cerebrovascular reactivity in the murine brain showed widespread brain changes resulting from the chronic IOP elevation and demonstrates vascular involvement in glaucoma both within and beyond the primary visual pathways.
At ARVO 2022, Jason S. Slakter, MD, presents data on the efficacy and safety of OPT-302 when combined with ranibizumab for polypoidal choroidal vasculopathy.
In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Mamoru Ogawa, MD, noted that investigators have found that the choroidal and central corneal thicknesses increased over a very short period of time following intensive outdoor activity.
Results from our recent poll regarding ARVO 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in person in Denver, Colorado.
A poll for retina specialists regarding their attendance at the Association for Research in Vision and Ophthalmology 2022 Meeting in Denver, Colorado. This poll is now closed.
Presenters at the conference provided new evidence about detecting geography atrophy and wet and dry AMD early and predicting disease progression. Investigators are also focused on finding cures for inherited retinal diseases.
Lisa Nijm, MD, advises young ophthalmologists on how to find common ground with their preferred practice and find solutions in the negotiation process that will help both parties flourish.
Dr. Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.
Dr. Stacy Pineles discusses the additional degree opportunities within the residency program at the Jules Stein Eye Institute at UCLA.
At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.
Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wet AMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.
A brief overview of findings presented at the 2022 Angiogenesis, Exudation and Degeneration meeting hosted by Bascom Palmer.
Investigators in the Netherlands have developed an RNA therapy to halt the progression of Stargardt disease.
Dr. Carel Hoyng divulges the main takeaways from his Angiogenesis presentation, including the origins of Stargardt disease, correct diagnosis, ongoing gene therapy trials and the future of therapy.
Dr. Carl Regillo discusses the 100-week results of KESTREL and KITE, two pivotal Phase 3 studies for brolucizumab for the treatment of diabetic macular edema.
Dr. Arshad M. Khanani reviews the Phase 2 part A results of the KALAHARI study of THR-149 for the treatment of DME.
KALAHARI study finds THR-149 to be safe, well-tolerated with preliminary efficacy as treatment for DME patients who respond suboptimally to anti-VEGF.
Advertisement
Advertisement
